Skip to main content
SpringerLink
Log in

Klären Sie Ihre Patienten über die Fortschritte auf

Chemotherapie: besser als ihr Ruf

Chemotherapy is better than its reputation: important developments within the last decades

  • FORTBILDUNG_SCHWERPUNKT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Die Angst der Patienten vor Nebenwirkungen der Chemotherapie wie Übelkeit, Erbrechen und erhöhte Infektanfälligkeit ist immer noch sehr groß. Doch Fortschritte der Supportivtherapie haben beeindruckende Verbesserungen gebracht. Wie verträglich die Chemotherapie heute ist und welche Fortschritte es bei der Behandlung gibt, schildert der nachfolgende Beitrag.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6

Literatur

  1. Cavalli F, Sonntag RW, Ryssel HJ, Tschopp L, Brunner KW. [First therapeutic experience with cis-platinum(II)diamindichloride (NSC 119875) in metastasizing ovarian and testicular carcinoma]. Schweiz Med Wochenschr. 1976 May 29;106(22):754–7. German. PubMed PMID: 996494.

    CAS  PubMed  Google Scholar 

  2. Stuart-Harris R, Buckman R, Starke I, Wiltshaw E. Chlorpromazine, placebo and droperidol in the treatment of nausea and vomiting associated with cisplatin therapy. Postgrad Med J. 1983 Aug;59(694):500–3. PubMed PMID: 6353396; PubMed Central PMCID: PMC2417595.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Sledge GW Jr, Einhorn L, Nagy C, House K. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer. 1992 Nov 15;70(10):2524–8. PubMed PMID: 1423181.

    Article  PubMed  Google Scholar 

  4. Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, Lisyanskaya A, Gralla RJ. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014 Jul;25(7):1340–6. doi: 10.1093/annonc/mdu110. Epub 2014 Mar 7. PubMed PMID: 24608196; PubMed Central PMCID: PMC4071755.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, Dittrich I, Schweisfurth H, von Weikersthal LF, Raghavachar A, Reissig A, Serke M. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol. 2005 Nov 20;23(33):8389–95. PubMed PMID: 16293869.

    Article  CAS  PubMed  Google Scholar 

  6. Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, Kuderer NM, Langston AA, Marr KA, Rolston KV, Ramsey SD. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013 Feb 20;31(6):794–810. doi: 10.1200/JCO.2012.45.8661. Epub 2013 Jan 14. PubMed PMID: 23319691.

    Article  PubMed  Google Scholar 

  7. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998 Aug;16(8):2672–85. PubMed PMID:9704717.

    CAS  PubMed  Google Scholar 

  8. von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, Zahm DM, Kümmel S, Eidtmann H, Klare P, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching PA, Sinn BV, Engels K, Mehta K, Nekljudova V, Untch M. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014 Jun;15(7):747–56. doi: 10.1016/S1470-2045(14)70160-3. Epub 2014 Apr 30. PubMed PMID: 24794243

    Article  Google Scholar 

  9. Elias L, Portlock CS, Rosenberg SA. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer. 1978 Oct;42(4):1705–10. PubMed PMID: 361209.

    Article  CAS  PubMed  Google Scholar 

  10. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235–42. PubMed PMID: 11807147.

    Article  CAS  PubMed  Google Scholar 

  11. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008 Feb;9(2):105–16. doi: 10.1016/S1470-2045(08)70002-0. Epub 2008 Jan 15. PubMed PMID: 18226581.

    Article  CAS  PubMed  Google Scholar 

  12. Lovly, C., L. Horn, W. Pao. 2015. Molecular Profiling of Lung Cancer. My Cancer Genome http://www.mycancergenome.org/content/disease/lung-cancer/ (Updated June 17)

  13. Burdett S, Stewart L, Auperin A, Pignon JP. Chemotherapy in non-small-cell lung cancer: an update of an individual patient data meta-analysis. J Clin Oncol. 2005 Feb 1;23(4):924–5; author reply 925-6. PubMed PMID: 15681545.

    Article  PubMed  Google Scholar 

  14. Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts JG, Morando C, Loundou A, Groen HJ, Rittmeyer A. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol. 2014 May;25(5):1044–52. doi: 10.1093/annonc/mdu098. Epub 2014 Feb 27. PubMed PMID: 24585722.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Halderstr. 29, D-86150, Augsburg, Deutschland

    Bernhard Heinrich (Hämatologisch onkologische Praxis Brudler/Heinrich/Bangerter)

  2. Augsburg, Deutschland

    Olaf Brudler (Hämatologisch onkologische Praxis Brudler/Heinrich/Bangerter) &  Markus Bangerter (Hämatologisch onkologische Praxis Brudler/Heinrich/Bangerter)

Authors
  1. Bernhard Heinrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olaf Brudler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Markus Bangerter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernhard Heinrich.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heinrich, B., Brudler, O. & Bangerter, M. Chemotherapie: besser als ihr Ruf. MMW - Fortschritte der Medizin 157, 39–44 (2015). https://doi.org/10.1007/s15006-015-3417-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-015-3417-3

Keywords

Search

Navigation